Pharmaceuticals

Kidney Fibrosis Treatment Market Dynamics 2026: Future Outlook and Key Insights

February 16, 2026February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the kidney fibrosis treatment market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Kidney Fibrosis Treatment Market between 2026 and 2030?

The kidney fibrosis treatment market size has demonstrated significant growth in recent years. It is projected to increase from $6.06 billion in 2025 to $6.54 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.0%. This expansion during the historical period can be attributed to factors such as the rising occurrence of chronic kidney disease, the limited efficacy of traditional therapies, the increased adoption of ACE inhibitors and ARBs, the growing healthcare strain from renal failure, and the broadened provision of nephrology care services.

The kidney fibrosis treatment market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $8.84 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.8%. This growth during the forecast period is attributable to advancements in targeted antifibrotic agents, an increasing aging population affected by CKD, the growing adoption of precision medicine in nephrology, rising investment in renal research, and improved diagnosis of early-stage kidney disease. Major trends expected in the forecast period include a heightened focus on antifibrotic drug development, an expanding use of combination therapies for CKD, increased research in stem cell and regenerative therapies, the expansion of early diagnostic and monitoring tools, and a rising number of clinical trials targeting renal fibrosis pathways.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Kidney Fibrosis Treatment Market?

The rising incidence of chronic kidney diseases is anticipated to stimulate expansion in the kidney fibrosis treatment market. Chronic kidney disease (CKD) involves a progressive decline in kidney function over time, frequently caused by conditions like diabetes or hypertension, leading to the build-up of waste products within the body. The growing prevalence of CKD is primarily fueled by increasing diabetes rates, which harm renal blood vessels and hinder their filtering capacity. Kidney fibrosis treatment aids CKD patients by addressing the scarring of kidney tissue, alleviating inflammation, and decelerating the advance of kidney damage, thereby sustaining kidney function. For instance, in July 2025, according to Hamadan University of Medical Sciences, a Iran-based university, the global number of newly diagnosed chronic kidney diseases is projected to rise to 25.06 million by 2030. Consequently, the increasing prevalence of chronic kidney diseases is propelling growth within the kidney fibrosis treatment market.

How Is The Kidney Fibrosis Treatment Market Organized Into Various Segments?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

What Long-Term Trends Are Expected To Shape The Future Of The Kidney Fibrosis Treatment Market?

Major companies active in the kidney fibrosis treatment market are directing their efforts towards targeted ileal-release immunomodulatory therapies, such as NEFECON. This oral delayed-release budesonide capsule specifically delivers the drug to the distal ileum to modulate gut-associated B-cells and decrease pathogenic IgA production, consequently slowing the progression of kidney fibrosis in IgA nephropathy patients. For instance, in June 2024, Everest Medicines, a biopharmaceutical company based in China, launched NEFECON. The therapy is formulated with an enteric-coated, delayed-release design to minimize systemic steroid exposure, targets mucosal B-cells in the gut to address the core issue of IgA nephropathy, and has shown significant ability to reduce the decline in kidney function.

Who Are The Top-Performing Companies In The Kidney Fibrosis Treatment Market In Recent Years?

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Kidney Fibrosis Treatment Market?

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Kidney Fibrosis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24271&type=smp

Browse Through More Reports Similar to the Global Kidney Fibrosis Treatment Market 2026, By The Business Research Company

Chronic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Late Stage Chronic Kidney Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795